The FDA has granted Breakthrough Therapy Designation to Bristol Myers Squibb (BMY) and SystImmune’s experimental drug iza-bren for treating advanced EGFR-mutant lung cancer after prior therapies fail, ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top stocks sold by hedge funds. On July 28, Bristol Myers, in ...

Systlmmune and BMS’ ACD treats patients with previously treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer.

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

The 31st One Mind Music Festival on September 13, 2025 will be hosted at Staglin Family Vineyard in Rutherford, CA. The ...

Our Bristol Myers Squibb Operating Income Comparison dashboard has more details. The company’s earnings stood at $2.97 on a per-share and reported basis in 2022, compared to the $2.02 figure in ...

Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird ...

Bristol Myers Squibb (BMY 0.07%) is one of the best-known healthcare companies in the world. Its roots go back to the 1800s, and it has continually evolved and gotten bigger over the years.

Bristol Myers Squibb’s revenue of $11.9 billion in Q2 was up 2% y-o-y, and its EPS of $1.93 reflected an 18% growth. This compares with our estimates of $11.5 billion and $1.86, respectively.